August - 2015
| Previous Next | Showing Journal 3 of 6 |
Idarucizumab for Dabigatran ReversalCharles V Pollack, Paul A Reilly, John Eikelboom, et al NEJM, 2015, 373:511-520 This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
August |
Previous Comments
No Comments yet.
Comment
The new non-vitamin K oral anticoagulant thrombin inhibitors have challenged acute health providers because of difficulty reversing their effects when bleeding occurs. Idarucizumab, a monoclonal antibody fragment, binds dabigatran with 350 times the...